摘要目的 观察特异性抑制富含半胱氨酸蛋白61(CCN1)对氧诱导视网膜病变(OIR)模型小鼠视网膜新生血管(RNV)的抑制作用.方法 7日龄C57BL/6J小鼠120只,随机分为对照组和实验组,每组各60只.参照文献方法制备OIR模型.小鼠出氧箱前1d即鼠龄11d时,对照组、实验组小鼠玻璃体腔分别注射空载体质粒、CCN1siRNA表达质粒各1μl.视网膜铺片观察视网膜血管形态,病理切片计数突破视网膜内界膜的血管内皮细胞核数,免疫组织化学、蛋白免疫印迹法、实时定量聚合酶链反应检测CCN1、血管内皮生长因子(VEGF)蛋白及mRNA的表达情况.结果 与对照组比较,实验组小鼠视网膜血管分布规则、分支良好、新生血管密度减少.两组间突破视网膜内界膜的血管内皮细胞核数量比较,差异有统计学意义(t=8.756,P＜0.05);CCN1、VEGF蛋白表达量比较,差异均有统计学意义(t=3.253、5.365,P＜0.05);CCN1、VEGF蛋白相对表达量比较,差异均有统计学意义(t=4.573、5.323,P＜0.05);CCN1、VEGFmRNA相对表达量比较,差异均有统计学意义(t=6.724、9.153,P＜0.05).结论 特异性抑制CCN1能有效抑制OIR模型小鼠RNV形成.

abstractsObjective To explore the inhibition effect of Cysteine-rich 61 (CCN1; Cyr61) specific siRNA expression vector on RNV in a mouse model of oxygen-induced retinopathy (OIR).Methods One hundred and twenty healthy C57BL/6J mice were chosen and randomly divided into the experimental group and control group,with 60 mice in each group.The experimental group was intravitreously injected with CCN1siRNA recombinant plasmids.The control group was injected with vector plasmids.Adenosine diphosphate-ase stained retina flat-mounts was performed to assess the retinal vascular profiles,retinal section with HE staining was applied to count the number of new vascular cell nuclei and the protein and mRNA expression of CCN1 and vascular endothelial growth factor (VEGF) were detected by immunohistochemistry,Western blot and Real-time RT-PCR.Results Compared with control group,regular distributions,good branches and reduced density of retinal neovascularization were observed in the experimental group.The number of nucleus of vascular endothelial cells breaking through the inner limiting membrane was obviously less in the experimental group than that in the control group (t=8.756,P＜ 0.05).The expression of CCN1 and VEGF were obviously decreased in the experimental group compared with the control group (all P＜0.05).Conclusion The development of RNV of ROP can be markedly inhibited by RNA interference targeting CCN1,and CCNlsiRNA may provide an effective method for preventing vascular proliferative retinopathy.